4

PTO/SB/05 (08-00)

Approved for use through 10/31/2002 OMB 0651-0032 U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

UTILITY PATENT APPLICATION **TRANSMITTAL**

Attorney Docket No. EU 98055 CON Jack L. Arbiser First Inventor CURCUMIN AND CURCUMINOID INHIBITION OF ANGIOGENESIS

Express Mail Labol No. | FL 709 418 650 US

Totaly for new monprovision	iai applications under 37 CFR 1.53(b),	Expres	S Mail Label No.		110 00	<u> </u>		
APPLICATION ELEMENTS					Commissiont Applicati	oner for Patents on		
See MPEP chapter 600 cond		Washingto	on, DC 20:	231				
1. Fee Transmittal For (Submit an original and a Applicant claims is See 37 CFR 1 27. 3. Specification (preferred arrangement - Descriptive title - Cross Reference - Statement Register - Reference to see or a computer p	orm (e.g., PTO/SB/17) displicate for fee processing) mall entity status. [Total Pages 25] t set forth below) of the invention e to Related Applications arding Fed sponsored R & D equence listing, a table, program listing appendix	7	CD-ROM or CD-Computer Progricleotide and/or Aminifapplicable, all neces Computer Rea Specification Seque i. CD-ROM of paper Statements ve	am (Appe. no Acid Se sary) idable Fori nce Listing or CD-R (2	endix) equence S m (CRF) g on: ccopies); c	ubmission or		
- Brief Summary	Background of the InventionBrief Summary of the Invention		ACCOMPANYING APPLICATION PARTS					
- Brief Descriptio - Detailed Descri - Claim(s) - Abstract of the	Disclosure	9 10. 11.	Assignment Pa 37 CFR 3 73(b (when there is English Transla	pers (cove) Stateme <i>an assign</i> ation Docu	er sheet & ent nee)	document(s)) Power of Attorney		
5. Oath or Declaration	[Total Pages 2]	12.	Information Dis		₁₄₉	Citations		
b. Copy from a (for continual signed standard in the following standar	uted (original or copy) prior application (37 CFR 1.63 (d)) tion/divisional with Box 17 completed) ION OF INVENTOR(S) tement attached deleting inventor(s) he prior application, see 37 CFR and 1 33(b) Sheet. See 37 CFR 1 76	13. 14. 15. 16.	Return Receip (Should be specified Copy (If foreign prior	nendment ot Postcard ecifically it	t d (MPEP 5 temized) y Docume med)	503)		
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1		aumalii tha ras	wiaita information ha	low and in	a prolimi	an i amandment		
17. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment or in an Application Data Sheet under 37 CFR 1.76: Continuation Divisional Continuation—in-part (CIP) of prior application No						•		
Prior application information	Examiner Kim, J.		Group / Art Unit16	1/				
For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the account and the continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion as seen in a very entity omitted from the submitted application parts. 18. CORRESPONDENCE ADDRESS								
10. GORRESPONDENCE ADDRESS								
Customer Number or Bar Code Label 23579 PATENT_TRADEMARK OFFICE Or Correspondence address below					dress below			
Name	Patrea L. Pabst Arnall Golden & Gregory, LL	P						
	2800 One Atlantic Center							
Address	1201 West Peachtree Street							
City	Atlanta	State	GA	Z	ip Code	30309-3450		
Country	United States	Telephone	(404) 873-8794	1	Fax	(404)873-8795		
Name (Print/Type)	Patrea L. Pabst	Re	gistration No. (Atto	orney/Age	ent) 31	1,284		
Signature	11-11			Da	te //	8/1001		

Burden Hour Statement This form is estimated to take 0.2 hours to complete Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS SEND TO Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231. EU 98055 CON 14194/2

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

FEE TRANSMITTAL for FY 2001

Patent fees are subject to annual revision

TOTAL AMOUNT OF PAYMENT

Signature

(\$)355.00

Complete if Known				
Application Number	Continuation of 09/345,712	_		
Filing Date	January 18, 2001	o TC		
First Named Inventor	Jack L. Arbiser	.6		
Examiner Name		S. S.		
Group Art Unit		9		
Attorney Docket No.	EU 98055 CON	80		

METHOD OF PAYMENT (check one)	FEE CALCULATION (continued)	<u>.</u>		
1. The Commissioner is hereby authorized to charge	3. ADDITIONAL FEES			
Deposit Deposit	Large Entity Small Entity Fee Fee Fee Fee Fee Fee Description Fe	a Daid		
Account Number 01-2507	Code (\$) Code (\$)	e Paid		
Deposit A HOLL OF	105 130 205 65 Surcharge - late filing fee or oath			
Account Name Arnall Golden & Gregory, LLC	127 50 227 25 Surcharge - late provisional filing fee or cover sheet			
Charge Any Additional Fee Required Under 37 CFR 1 16 and 1 17	139 130 139 130 Non-English specification			
Applicant claims small entity status	147 2,520 147 2,520 For filing a request for ex parte reexamination			
2. X Payment Enclosed:	112 920* 112 920* Requesting publication of SIR prior to Examiner action			
Check Credit card Money Other	113 1,840* 113 1,840* Requesting publication of SIR after Examiner action			
FEE CALCULATION	115 110 215 55 Extension for reply within first month]		
	116 390 216 195 Extension for reply within second month			
1. BASIC FILING FEE Large Entity Small Entity	117 890 217 445 Extension for reply within third month			
Fee Fee Fee Fee Description	118 1.390 218 695 Extension for reply within fourth month			
404 740 004 055 11114 61 6	128 1,890 228 945 Extension for reply within fifth month] [
101 710 201 355 Utility filing fee 355.00	119 310 219 155 Notice of Appeal			
107 490 207 245 Plant filing fee	120 310 220 155 Filing a brief in support of an appeal			
108 710 208 355 Reissue filing fee	121 270 221 135 Request for oral hearing	}]		
114 150 214 75 Provisional filing fee	138 1,510 138 1,510 Petition to institute a public use proceeding			
	140 110 240 55 Petition to revive - unavoidable			
SUBTOTAL (1) (\$) 355.00	141 1,240 241 620 Petition to revive - unintentional			
2. EXTRA CLAIM FEES	142 1.240 242 620 Utility issue fee (or reissue)			
Fee from Extra Claims below Fee Paid	143 440 243 220 Design issue fee			
Total Claims 8 - 20 = 0 X =	144 600 244 300 Plant issue fee			
Independent 3 - 3 = 0 X =	122 130 122 130 Petitions to the Commissioner			
Multiple Dependent	123 50 123 50 Petitions related to provisional applications			
	126 240 126 240 Submission of Information Disclosure Stmt			
Large Entity Small Entity Fee Fee Fee Fee Description Code (\$) Code (\$)	581 40 581 40 Recording each patent assignment per property (times number of properties)			
103 18 203 9 Claims in excess of 20	146 710 246 355 Filing a submission after final rejection			
102 80 202 40 Independent claims in excess of 3	(37 CFR § 1 129(a))			
104 270 204 135 Multiple dependent claim, if not paid	149 710 249 355 For each additional invention to be examined (37 CFR § 1.129(b))			
109 80 209 40 ** Reissue independent claims over original patent	179 710 279 355 Request for Continued Examination (RCE)			
110 18 210 9 ** Reissue claims in excess of 20 and over original patent	169 900 169 900 Request for expedited examination of a design application			
and over original patent	Other fee (specify)			
SUBTOTAL (2) (\$) 0	Reduced by Basic Filing Fee Paid SUBTOTAL (3) (\$)			
	According to talk			
SUBMITTED BY	Complete (if applicable)			

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

January 18,

Date

Continuation of U.S.S.N. 09/345,712

Filed: January 18, 2001

PRELIMINARY AMENDMENT
Express Mail Label No. EL 709 418 650 US

Date of Deposit: January 18, 2001

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.10

I hereby certify that this PRELIMINARY AMENDMENT and any documents referred to as attached therein are being deposited with the United States Postal Service on this date, January 18, 2001, in an envelope as "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10, Mailing Label Number EL 709 418 650 US addressed to Box Patent Application, Assistant Commissioner of Patents and Trademarks, Washington, D.C. 20231.

Sunny G. Johns

Date: January 18, 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Jack L. Arbiser

Serial No:

Continuation of 09/345,712

Express Mail Label

No. EL 709 418 650 US

Filed:

January 18, 2001

Date of Deposit: January 18, 2001

For:

CURCUMIN AND CURCUMINOID INHIBITION OF ANGIOGENESIS

BOX PATENT APPLICATION Assistant Commissioner of Patents Washington, D.C. 20231

REQUEST FOR FILING A CONTINUATION APPLICATION UNDER 37 C.F.R. § 1.53(b)

Sir:

This is a request for filing a continuation application under 37 C.F.R. § 1.53(b), of copending prior application U.S.S.N. 09/345,712 filed June 30, 1999, entitled "Curcumin and Curcuminoid Inhibition of Angiogenesis", by Jack L. Arbiser. The application includes 1 page of abstract, 22 pages of specification, 2 pages of claims, 3 sheets of formal drawings, and the executed Declaration for Patent Application from prior application U.S.S.N. 09/345,712.

A Preliminary Amendment and an Information Disclosure Statement are enclosed.

Applicants enclose from prior application U.S.S.N 09/345,712 filed June 30, 1999, copies of the (1) executed Assignment from Jack L. Arbiser to Emory University, recorded

Continuation of U.S.S.N. 09/345,712

Filed: January 18, 2001

REQUEST FOR FILING A CONTINUATION

APPLICATION UNDER 37 C.F.R. § 1.53(b)

Express Mail Label No. EL 709 418 650 US

Date of Deposit: January 18, 2001

September 1, 1999, at Reel 010207, Frame 0564; and (2) executed Statement Under 37 C.F.R.

§ 3.73(b) by Emory University.

This application claims small entity status pursuant to 37 C.F.R. § 1.27.

A check in the amount of \$355.00 to cover the filing fee for a small entity is enclosed.

It is believed that this is the proper filing fee since the application includes a total of eight claims

and three independent claims following entry of the enclosed Preliminary Amendment.

The Commissioner is hereby authorized to charge any additional fees that may be

required, or credit any overpayment to Deposit Order Account No. 01-2507. To facilitate this

process, applicants have enclosed a duplicate of this letter.

This application is being filed on January 18, 2001, by mailing the application to Box

Patent Application, Assistant Commissioner for Patents, Washington, D.C. 20231 via the United

States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10.

The Express Mail label number appears in the heading of this paper which is attached to the

application papers pursuant to 37 C.F.R. § 1.10(b).

2

tant iv iv tank iv the line is not and fain that their tank

Continuation of U.S.S.N. 09/345,712 Filed: January 18, 2001 REQUEST FOR FILING A CONTINUATION APPLICATION UNDER 37 C.F.R. § 1.53(b) Express Mail Label No. EL 709 418 650 US Date of Deposit: January 18, 2001

All correspondence concerning this application should be mailed to:

Patrea L. Pabst, Esq. ARNALL GOLDEN & GREGORY, LLP 2800 One Atlantic Center 1201 West Peachtree Street Atlanta, Georgia 30309-3450

Respectfully submitted,

Patrea L. Pabst Reg. No. 31,284

Date: January 18, 2001

ARNALL GOLDEN & GREGORY, LLP 2800 One Atlantic Center 1201 West Peachtree Street Atlanta, Georgia 30309-3450 (404) 873-8794 (404) 873-8795 (fax) PTO/SB/96 (6-98)

Approved for use through 09/30/2000. OMB 0651-0031

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

STATEMEN	11 UNDER 37 CFR 3.73(b)
Applicant/PatentOwner: Jack L. Arbiser	
Application No./Patent No.: 09/345,712	Filed/IssueDate: June 30, 1999
Entitled: CURCUMIN AND CURCUMINOID INHII	BITION OF ANGIOGENESIS
Emory University	University
	Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)
states that it is:	
1. Kithe assignee of the entire right, title, and interes	st; or
2. an assignee of an undivided part interest	
in the patent application/patent identified above by virtu	e of either:
	application/patent identified above. The assignment was recorded in the me, or for which a copy thereof is attached.
OR	
B. [] A chain of title from the inventor(s), of the patent ap	oplication/patentidentified above, to the current assignee as shown below:
From: The document was recorded in the Patent a Reel, Frame, or for	
From: The document was recorded in the Patent a Reel, Frame, or for	
3. From:	
[] Additional documents in the chain of title	are listed on a supplemental sheet.
[] Copies of assignments or other documents in the characteristic [NOTE: A separate copy (i.e., the original assignment must be submitted to Assignment Division in accordance recorded in the records of the PTO. See MPEP 302-	nt document or a true copy of the original document) dance with 37 CFR Part 3, if the assignment is to be
The undersigned (whose title is supplied below) is empored. August 20, 1999 Date	wered to sign this statement on behalf of the assignee. Augusta Signature Paul L. Carey
	Typed or printed name
	Director, Office of Technology Transfer Title
	· ido